Cargando…

Isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma patients with high‐risk cytogenetics: IKEMA subgroup analysis

INTRODUCTION: The presence of high‐risk chromosomal abnormalities [t(4;14), del(17p), and t(14;16)] has been linked with inferior outcomes in patients with multiple myeloma (MM). A prespecified interim analysis of the Phase 3 IKEMA study (NCT03275285) demonstrated that isatuximab (Isa) + carfilzomib...

Descripción completa

Detalles Bibliográficos
Autores principales:	Spicka, Ivan, Moreau, Philippe, Martin, Thomas G., Facon, Thierry, Martinez, Gracia, Oriol, Albert, Koh, Youngil, Lim, Andrew, Mikala, Gabor, Rosiñol, Laura, Yağci, Münci, Cavo, Michele, Risse, Marie‐Laure, Asset, Gaëlle, Macé, Sandrine, van de Velde, Helgi, Yong, Kwee
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9804737/ https://www.ncbi.nlm.nih.gov/pubmed/35871357 http://dx.doi.org/10.1111/ejh.13835

Ejemplares similares

Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in elderly patients with relapsed multiple myeloma: IKEMA subgroup analysis
por: Facon, Thierry, et al.
Publicado: (2022)

Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study
por: Martin, Thomas, et al.
Publicado: (2023)

Correction: Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study
por: Martin, Thomas, et al.
Publicado: (2023)

P916: LONG-TERM OUTCOMES WITH ISATUXIMAB-CARFILZOMIB-DEXAMETHASONE (ISA-KD) IN RELAPSED MULTIPLE MYELOMA PATIENTS WITH 1Q21+ STATUS: UPDATED RESULTS FROM THE PHASE 3 IKEMA STUDY
por: Facon, Thierry, et al.
Publicado: (2023)

Isatuximab plus carfilzomib and dexamethasone in patients with relapsed multiple myeloma based on prior lines of treatment and refractory status: IKEMA subgroup analysis
por: Dimopoulos, Meletios A., et al.
Publicado: (2022)

P931: ISATUXIMAB IN RELAPSED MULTIPLE MYELOMA PATIENTS WITH ULTRA-HIGH-RISK CYTOGENETICS: ICARIA-MM AND IKEMA SUBGROUP ANALYSIS
por: Moreau, Philippe, et al.
Publicado: (2023)

Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in relapsed multiple myeloma patients with renal impairment: IKEMA subgroup analysis
por: Capra, Marcelo, et al.
Publicado: (2021)

Primary outcomes by 1q21+ status for isatuximab-treated patients with relapsed/refractory multiple myeloma: subgroup analyses from ICARIA-MM and IKEMA
por: Martin, Tom, et al.
Publicado: (2022)

Depth of response and response kinetics of isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma
por: Martin, Thomas, et al.
Publicado: (2022)

Isatuximab plus carfilzomib and dexamethasone in Japanese patients with relapsed multiple myeloma: subgroup analysis of the randomized, open label, phase 3 IKEMA study
por: Ishida, Tadao, et al.
Publicado: (2022)

P968: ALLOCATION AND VALIDATION OF THE SECOND REVISION OF THE INTERNATIONAL STAGING SYSTEM IN THE ICARIA-MM AND IKEMA STUDIES
por: Perrot, Aurore, et al.
Publicado: (2023)

Predictive biomarkers with isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma
por: Richardson, Paul G., et al.
Publicado: (2021)

Carfilzomib–dexamethasone vs bortezomib–dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR
por: Chng, W-J, et al.
Publicado: (2017)

Subgroup analysis of ICARIA‐MM study in relapsed/refractory multiple myeloma patients with high‐risk cytogenetics
por: Harrison, Simon J., et al.
Publicado: (2021)

PK/PD modeling analysis for dosing regimen selection of isatuximab as single agent and in combination therapy in patients with multiple myeloma
por: Koiwai, Kimiko, et al.
Publicado: (2021)

Therapeutic Opportunities with Pharmacological Inhibition of CD38 with Isatuximab
por: Martin, Thomas G., et al.
Publicado: (2019)

Carfilzomib–lenalidomide–dexamethasone vs lenalidomide–dexamethasone in relapsed multiple myeloma by previous treatment
por: Dimopoulos, M A, et al.
Publicado: (2017)

Matching‐adjusted indirect comparison of isatuximab plus carfilzomib and dexamethasone with daratumumab plus lenalidomide and dexamethasone in relapsed multiple myeloma
por: Richter, Joshua, et al.
Publicado: (2023)

Antibody interference and response kinetics of isatuximab plus pomalidomide and dexamethasone in multiple myeloma
por: Hulin, Cyrille, et al.
Publicado: (2021)

Isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients with renal impairment: ICARIA-MM subgroup analysis
por: Dimopoulos, Meletios A., et al.
Publicado: (2020)

A phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumab
por: Mikhael, Joseph, et al.
Publicado: (2021)

P902: ISATUXIMAB, WEEKLY CARFILZOMIB AND DEXAMETHASONE AS SALVAGE THERAPY FOR RRMM; INTERIM RESULTS FROM A PHASE 2 TRIAL.
por: Vesole, David H., et al.
Publicado: (2023)

Isatuximab plus pomalidomide and dexamethasone in elderly patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis
por: Schjesvold, Fredrik, et al.
Publicado: (2021)

Isatuximab plus pomalidomide and dexamethasone in elderly patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis
por: Schjesvold, Fredrik, et al.
Publicado: (2022)

Isatuximab in combination with cemiplimab in patients with relapsed/refractory multiple myeloma: A phase 1/2 study
por: Lesokhin, Alexander, et al.
Publicado: (2023)

Phase 1b trial of isatuximab, an anti‐CD38 monoclonal antibody, in combination with carfilzomib as treatment of relapsed/refractory multiple myeloma
por: Martin, Thomas G., et al.
Publicado: (2021)

Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed multiple myeloma categorised by age: secondary analysis from the phase 3 ASPIRE study
por: Dimopoulos, Meletios A., et al.
Publicado: (2017)

Isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) in front-line treatment of high-risk multiple myeloma: interim analysis of the GMMG-CONCEPT trial
por: Leypoldt, Lisa B., et al.
Publicado: (2021)

Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR study
por: Moreau, P, et al.
Publicado: (2017)

Joint modelling and simulation of M‐protein dynamics and progression‐free survival for alternative isatuximab dosing with pomalidomide/dexamethasone
por: Thai, Hoai‐Thu, et al.
Publicado: (2021)

Exposure‐response analyses for selection/confirmation of optimal isatuximab dosing regimen in combination with pomalidomide/dexamethasone treatment in patients with multiple myeloma
por: Rachedi, Fatiha, et al.
Publicado: (2022)

P907: CARFILZOMIB, DEXAMETHASONE, AND DARATUMUMAB (KDD) VS CARFILZOMIB AND DEXAMETHASONE (KD) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): FRAILTY SUBGROUP ANALYSIS OF THE CANDOR STUDY
por: Quach, H., et al.
Publicado: (2022)

Daratumumab, carfilzomib, and dexamethasone in relapsed or refractory myeloma: final analysis of PLEIADES and EQUULEUS
por: Moreau, Philippe, et al.
Publicado: (2023)

P945: SUBCUTANEOUS ISATUXIMAB ADMINISTRATION BY AN ON-BODY DELIVERY SYSTEM IN COMBINATION WITH POMALIDOMIDE-DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS: INTERIM PHASE 1B STUDY RESULTS
por: Quach, H., et al.
Publicado: (2022)

Drug‐Disease Interaction and Time‐Dependent Population Pharmacokinetics of Isatuximab in Relapsed/Refractory Multiple Myeloma Patients
por: Fau, Jean‐Baptiste, et al.
Publicado: (2020)

Isatuximab: A Review of Its Use in Multiple Myeloma
por: Frampton, James E.
Publicado: (2021)

Isatuximab monotherapy in patients with refractory T‐acute lymphoblastic leukemia or T‐lymphoblastic lymphoma: Phase 2 study
por: Boissel, Nicolas, et al.
Publicado: (2022)

Correction to: Isatuximab: A Review of Its Use in Multiple Myeloma
por: Frampton, James E.
Publicado: (2021)

Isatuximab in the Treatment of Multiple Myeloma: A Review and Comparison With Daratumumab
por: Shen, Fei, et al.
Publicado: (2022)

Individualized genetic makeup that controls natural killer cell function influences the efficacy of isatuximab immunotherapy in patients with multiple myeloma
por: Sun, Haibo, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_sbc469an9f0r8nmsbh6ic2thog